Concepts (238)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Visual Acuity | 13 | 2025 | 119 | 3.780 |
Why?
|
| Astigmatism | 6 | 2025 | 11 | 3.430 |
Why?
|
| Cataract | 7 | 2025 | 26 | 3.420 |
Why?
|
| Descemet Stripping Endothelial Keratoplasty | 7 | 2025 | 9 | 3.340 |
Why?
|
| Lenses, Intraocular | 8 | 2025 | 19 | 3.180 |
Why?
|
| Corneal Diseases | 11 | 2022 | 25 | 3.100 |
Why?
|
| Phacoemulsification | 7 | 2025 | 20 | 2.660 |
Why?
|
| Refraction, Ocular | 9 | 2025 | 25 | 2.660 |
Why?
|
| Cornea | 17 | 2025 | 72 | 2.630 |
Why?
|
| Cataract Extraction | 5 | 2024 | 29 | 2.230 |
Why?
|
| Keratoconus | 5 | 2024 | 8 | 2.090 |
Why?
|
| Surgeons | 3 | 2022 | 50 | 2.050 |
Why?
|
| Lens Implantation, Intraocular | 7 | 2025 | 19 | 1.860 |
Why?
|
| Pseudophakia | 3 | 2025 | 6 | 1.670 |
Why?
|
| Contact Lenses | 3 | 2022 | 6 | 1.380 |
Why?
|
| Humans | 56 | 2025 | 28998 | 1.270 |
Why?
|
| Retrospective Studies | 19 | 2025 | 2644 | 1.240 |
Why?
|
| Vision Disorders | 2 | 2020 | 38 | 1.130 |
Why?
|
| Tomography, Optical Coherence | 4 | 2023 | 96 | 1.110 |
Why?
|
| Keratitis | 2 | 2022 | 31 | 1.100 |
Why?
|
| Biometry | 8 | 2024 | 20 | 0.990 |
Why?
|
| Eye Infections, Bacterial | 2 | 2022 | 129 | 0.980 |
Why?
|
| Endothelium, Corneal | 5 | 2024 | 8 | 0.950 |
Why?
|
| Sclera | 2 | 2022 | 11 | 0.900 |
Why?
|
| Descemet Membrane | 3 | 2021 | 4 | 0.860 |
Why?
|
| Corneal Neovascularization | 1 | 2024 | 3 | 0.850 |
Why?
|
| Photochemotherapy | 1 | 2024 | 42 | 0.820 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2024 | 108 | 0.800 |
Why?
|
| Limbus Corneae | 2 | 2020 | 3 | 0.740 |
Why?
|
| Fluorometholone | 1 | 2022 | 4 | 0.740 |
Why?
|
| Axial Length, Eye | 6 | 2023 | 9 | 0.730 |
Why?
|
| Female | 24 | 2025 | 15690 | 0.730 |
Why?
|
| Microsporidia | 1 | 2022 | 5 | 0.720 |
Why?
|
| Microsporidiosis | 1 | 2022 | 4 | 0.720 |
Why?
|
| Contact Lenses, Hydrophilic | 1 | 2021 | 2 | 0.700 |
Why?
|
| Refractive Errors | 1 | 2021 | 6 | 0.700 |
Why?
|
| Corneal Opacity | 1 | 2021 | 4 | 0.690 |
Why?
|
| Corneal Dystrophies, Hereditary | 1 | 2021 | 5 | 0.690 |
Why?
|
| Ophthalmologic Surgical Procedures | 1 | 2021 | 24 | 0.660 |
Why?
|
| Terminology as Topic | 1 | 2020 | 64 | 0.640 |
Why?
|
| Middle Aged | 17 | 2025 | 7428 | 0.620 |
Why?
|
| Comprehension | 1 | 2019 | 20 | 0.600 |
Why?
|
| Informed Consent | 1 | 2019 | 26 | 0.590 |
Why?
|
| Preoperative Care | 1 | 2019 | 81 | 0.580 |
Why?
|
| Patient Satisfaction | 1 | 2019 | 96 | 0.570 |
Why?
|
| Patient Education as Topic | 1 | 2019 | 92 | 0.570 |
Why?
|
| Charles Bonnet Syndrome | 1 | 2018 | 1 | 0.560 |
Why?
|
| Male | 20 | 2025 | 13983 | 0.560 |
Why?
|
| Corneal Stroma | 3 | 2023 | 6 | 0.550 |
Why?
|
| Optics and Photonics | 5 | 2024 | 23 | 0.550 |
Why?
|
| Anxiety | 1 | 2019 | 160 | 0.540 |
Why?
|
| Refractive Surgical Procedures | 1 | 2017 | 1 | 0.530 |
Why?
|
| Aged | 10 | 2025 | 5608 | 0.520 |
Why?
|
| Aged, 80 and over | 6 | 2025 | 2067 | 0.520 |
Why?
|
| Prosthesis Fitting | 3 | 2022 | 5 | 0.520 |
Why?
|
| Follow-Up Studies | 4 | 2025 | 1032 | 0.510 |
Why?
|
| Corneal Topography | 3 | 2025 | 4 | 0.500 |
Why?
|
| Corneal Endothelial Cell Loss | 2 | 2024 | 2 | 0.470 |
Why?
|
| Keratomileusis, Laser In Situ | 2 | 2024 | 3 | 0.460 |
Why?
|
| Achromobacter denitrificans | 1 | 2013 | 2 | 0.410 |
Why?
|
| Myopia | 2 | 2024 | 19 | 0.410 |
Why?
|
| Reproducibility of Results | 4 | 2025 | 788 | 0.410 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2013 | 22 | 0.400 |
Why?
|
| Choroid Diseases | 1 | 2012 | 1 | 0.390 |
Why?
|
| Optic Disk | 1 | 2012 | 10 | 0.390 |
Why?
|
| Fluorescein Angiography | 1 | 2012 | 18 | 0.380 |
Why?
|
| Prospective Studies | 4 | 2025 | 1283 | 0.380 |
Why?
|
| Surgical Wound Infection | 1 | 2013 | 108 | 0.380 |
Why?
|
| Choroid | 1 | 2012 | 21 | 0.380 |
Why?
|
| Cross-Sectional Studies | 4 | 2025 | 1004 | 0.380 |
Why?
|
| Cocaine-Related Disorders | 2 | 2003 | 17 | 0.370 |
Why?
|
| Brain | 1 | 2018 | 770 | 0.370 |
Why?
|
| Corneal Injuries | 2 | 2022 | 12 | 0.360 |
Why?
|
| Keratoplasty, Penetrating | 2 | 2022 | 2 | 0.360 |
Why?
|
| Gonadal Steroid Hormones | 2 | 2022 | 24 | 0.350 |
Why?
|
| Internship and Residency | 1 | 2014 | 263 | 0.320 |
Why?
|
| Calciphylaxis | 1 | 2009 | 4 | 0.310 |
Why?
|
| Penile Diseases | 1 | 2009 | 9 | 0.310 |
Why?
|
| Glaucoma Drainage Implants | 1 | 2009 | 10 | 0.310 |
Why?
|
| Lasers | 3 | 2023 | 68 | 0.290 |
Why?
|
| Prosthesis Design | 2 | 2025 | 88 | 0.280 |
Why?
|
| Treatment Outcome | 2 | 2025 | 2427 | 0.280 |
Why?
|
| Heart Failure | 2 | 2003 | 253 | 0.270 |
Why?
|
| United States | 3 | 2024 | 2247 | 0.270 |
Why?
|
| Multifocal Intraocular Lenses | 1 | 2025 | 1 | 0.240 |
Why?
|
| Mesopic Vision | 1 | 2025 | 1 | 0.240 |
Why?
|
| Color Vision | 1 | 2025 | 4 | 0.240 |
Why?
|
| Reading | 1 | 2025 | 19 | 0.230 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2024 | 75 | 0.230 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2024 | 128 | 0.220 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2024 | 37 | 0.220 |
Why?
|
| Enoxaparin | 1 | 2024 | 38 | 0.210 |
Why?
|
| Anti-Bacterial Agents | 2 | 2022 | 537 | 0.200 |
Why?
|
| Double-Blind Method | 2 | 2022 | 426 | 0.200 |
Why?
|
| Interferometry | 1 | 2023 | 11 | 0.200 |
Why?
|
| Diagnosis, Differential | 3 | 2013 | 379 | 0.200 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2024 | 179 | 0.200 |
Why?
|
| Hyperthyroidism | 1 | 2003 | 10 | 0.190 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2022 | 23 | 0.190 |
Why?
|
| Loteprednol Etabonate | 1 | 2022 | 2 | 0.190 |
Why?
|
| Myocardial Ischemia | 1 | 2003 | 73 | 0.180 |
Why?
|
| Ophthalmic Solutions | 1 | 2022 | 27 | 0.180 |
Why?
|
| Costs and Cost Analysis | 1 | 2022 | 40 | 0.180 |
Why?
|
| Extracellular Matrix | 1 | 2023 | 117 | 0.180 |
Why?
|
| Intraoperative Complications | 1 | 2022 | 47 | 0.180 |
Why?
|
| Estriol | 1 | 2022 | 3 | 0.180 |
Why?
|
| Estrone | 1 | 2022 | 5 | 0.180 |
Why?
|
| Collagen | 1 | 2023 | 156 | 0.180 |
Why?
|
| Aortic Aneurysm | 1 | 2002 | 16 | 0.180 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2002 | 43 | 0.180 |
Why?
|
| Gonadotropins | 1 | 2021 | 22 | 0.180 |
Why?
|
| Graft Rejection | 1 | 2022 | 34 | 0.180 |
Why?
|
| Extracellular Vesicles | 1 | 2022 | 54 | 0.180 |
Why?
|
| Receptors, Steroid | 1 | 2022 | 26 | 0.180 |
Why?
|
| Hormones | 1 | 2021 | 44 | 0.180 |
Why?
|
| Heart Conduction System | 1 | 2003 | 270 | 0.170 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2022 | 79 | 0.170 |
Why?
|
| Punctal Plugs | 1 | 2021 | 3 | 0.170 |
Why?
|
| Dry Eye Syndromes | 1 | 2021 | 5 | 0.170 |
Why?
|
| Aorta | 1 | 2002 | 124 | 0.170 |
Why?
|
| Immunoconjugates | 1 | 2021 | 21 | 0.170 |
Why?
|
| Adult | 8 | 2024 | 8048 | 0.160 |
Why?
|
| Exosomes | 1 | 2022 | 96 | 0.160 |
Why?
|
| Equipment Design | 1 | 2021 | 218 | 0.160 |
Why?
|
| Vaccination | 1 | 2022 | 213 | 0.160 |
Why?
|
| Single-Blind Method | 1 | 2019 | 47 | 0.150 |
Why?
|
| Glucocorticoids | 2 | 2024 | 115 | 0.150 |
Why?
|
| Digoxin | 1 | 1998 | 8 | 0.140 |
Why?
|
| Remission, Spontaneous | 1 | 2018 | 8 | 0.140 |
Why?
|
| Cardiotonic Agents | 1 | 1998 | 28 | 0.140 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 1998 | 117 | 0.130 |
Why?
|
| Tears | 3 | 2022 | 10 | 0.130 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 215 | 0.130 |
Why?
|
| Enzyme Inhibitors | 1 | 1998 | 251 | 0.130 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 481 | 0.110 |
Why?
|
| Child | 1 | 2021 | 2327 | 0.110 |
Why?
|
| Long QT Syndrome | 2 | 2006 | 15 | 0.110 |
Why?
|
| Cadaver | 1 | 2014 | 61 | 0.100 |
Why?
|
| Stem Cells | 1 | 2014 | 123 | 0.100 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2013 | 149 | 0.100 |
Why?
|
| Drug Therapy, Combination | 1 | 2013 | 210 | 0.100 |
Why?
|
| Fundus Oculi | 1 | 2012 | 15 | 0.100 |
Why?
|
| Cell Count | 2 | 2009 | 86 | 0.090 |
Why?
|
| Eye | 2 | 2022 | 36 | 0.090 |
Why?
|
| Uremia | 1 | 2010 | 5 | 0.080 |
Why?
|
| Calcinosis | 1 | 2010 | 25 | 0.080 |
Why?
|
| Retinal Diseases | 1 | 2011 | 47 | 0.080 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2010 | 64 | 0.080 |
Why?
|
| Gangrene | 1 | 2009 | 4 | 0.080 |
Why?
|
| Renal Insufficiency | 1 | 2010 | 20 | 0.080 |
Why?
|
| Penis | 1 | 2009 | 17 | 0.080 |
Why?
|
| Cardiology | 1 | 2010 | 48 | 0.080 |
Why?
|
| Corneal Transplantation | 1 | 2009 | 1 | 0.080 |
Why?
|
| Skin | 1 | 2010 | 153 | 0.080 |
Why?
|
| Intraocular Pressure | 1 | 2009 | 62 | 0.080 |
Why?
|
| Glaucoma | 1 | 2009 | 53 | 0.070 |
Why?
|
| Contrast Media | 1 | 2010 | 96 | 0.070 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2010 | 177 | 0.070 |
Why?
|
| Prognosis | 1 | 2009 | 812 | 0.060 |
Why?
|
| Electrocardiography | 2 | 2006 | 398 | 0.060 |
Why?
|
| Receptors, LHRH | 1 | 2024 | 17 | 0.050 |
Why?
|
| Postoperative Complications | 1 | 2009 | 635 | 0.050 |
Why?
|
| Fuchs' Endothelial Dystrophy | 1 | 2024 | 1 | 0.050 |
Why?
|
| Anterior Chamber | 1 | 2024 | 6 | 0.050 |
Why?
|
| Fibroblasts | 1 | 2024 | 160 | 0.050 |
Why?
|
| Torsades de Pointes | 1 | 2003 | 3 | 0.050 |
Why?
|
| Systole | 1 | 2003 | 24 | 0.050 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2003 | 20 | 0.050 |
Why?
|
| Syndrome | 1 | 2003 | 79 | 0.050 |
Why?
|
| Fatal Outcome | 1 | 2003 | 67 | 0.050 |
Why?
|
| Young Adult | 2 | 2024 | 2842 | 0.050 |
Why?
|
| Immersion | 1 | 2022 | 4 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2024 | 464 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2024 | 739 | 0.050 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2003 | 64 | 0.050 |
Why?
|
| Anticoagulants | 1 | 2024 | 297 | 0.050 |
Why?
|
| Mydriatics | 1 | 2022 | 6 | 0.050 |
Why?
|
| Patient Acuity | 1 | 2022 | 6 | 0.050 |
Why?
|
| Amnion | 1 | 2022 | 4 | 0.050 |
Why?
|
| Adhesives | 1 | 2022 | 6 | 0.050 |
Why?
|
| Receptors, Progesterone | 1 | 2022 | 17 | 0.050 |
Why?
|
| Receptors, Androgen | 1 | 2022 | 26 | 0.040 |
Why?
|
| Estrogen Receptor beta | 1 | 2022 | 14 | 0.040 |
Why?
|
| Stromal Cells | 1 | 2022 | 62 | 0.040 |
Why?
|
| Estrogen Receptor alpha | 1 | 2022 | 27 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 56 | 0.040 |
Why?
|
| RNA | 1 | 2022 | 111 | 0.040 |
Why?
|
| Acute Disease | 1 | 2022 | 156 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2022 | 74 | 0.040 |
Why?
|
| Fluorescent Dyes | 1 | 2022 | 93 | 0.040 |
Why?
|
| Wound Healing | 1 | 2022 | 126 | 0.040 |
Why?
|
| Povidone-Iodine | 1 | 2021 | 8 | 0.040 |
Why?
|
| Intravitreal Injections | 1 | 2021 | 34 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2021 | 26 | 0.040 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2021 | 32 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2021 | 102 | 0.040 |
Why?
|
| Lipids | 1 | 2022 | 220 | 0.040 |
Why?
|
| Renal Dialysis | 2 | 2011 | 53 | 0.040 |
Why?
|
| Cell Movement | 1 | 2022 | 376 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 1011 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2022 | 1022 | 0.040 |
Why?
|
| Biomarkers | 1 | 2022 | 782 | 0.040 |
Why?
|
| Myocardial Contraction | 1 | 1998 | 62 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 1998 | 50 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 1998 | 32 | 0.030 |
Why?
|
| Hemodynamics | 1 | 1998 | 221 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1998 | 612 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1998 | 413 | 0.030 |
Why?
|
| Anti-Allergic Agents | 1 | 2014 | 1 | 0.030 |
Why?
|
| Vitamin A | 1 | 2014 | 32 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2014 | 151 | 0.020 |
Why?
|
| Hyperoxaluria | 1 | 2011 | 1 | 0.020 |
Why?
|
| Hyperoxaluria, Primary | 1 | 2011 | 1 | 0.020 |
Why?
|
| Pyridoxine | 1 | 2011 | 1 | 0.020 |
Why?
|
| Subretinal Fluid | 1 | 2011 | 1 | 0.020 |
Why?
|
| Oxalates | 1 | 2011 | 3 | 0.020 |
Why?
|
| Papilledema | 1 | 2011 | 8 | 0.020 |
Why?
|
| Nystagmus, Pathologic | 1 | 2011 | 4 | 0.020 |
Why?
|
| Transaminases | 1 | 2011 | 10 | 0.020 |
Why?
|
| Necrosis | 1 | 2010 | 85 | 0.020 |
Why?
|
| Liver Transplantation | 1 | 2011 | 56 | 0.020 |
Why?
|
| Electroretinography | 1 | 2011 | 180 | 0.020 |
Why?
|
| Hospitals, Community | 1 | 2010 | 8 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2010 | 19 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 2010 | 26 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2010 | 69 | 0.020 |
Why?
|
| Air | 1 | 2009 | 23 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2010 | 150 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2009 | 73 | 0.020 |
Why?
|
| Patient Selection | 1 | 2010 | 151 | 0.020 |
Why?
|
| Microspheres | 1 | 2009 | 49 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2009 | 115 | 0.020 |
Why?
|
| Reoperation | 1 | 2009 | 155 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 249 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2010 | 245 | 0.020 |
Why?
|
| Infant | 1 | 2011 | 1049 | 0.020 |
Why?
|
| Defibrillators, Implantable | 1 | 2006 | 46 | 0.010 |
Why?
|
| Risk Factors | 1 | 2010 | 2134 | 0.010 |
Why?
|